Navigation Links
Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
Date:12/13/2011

MADISON, Wis., Dec 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced the commercial launch of human iCell® Neurons for use in neuroscience drug discovery, neurotoxicity screens, and other health research. This is the first commercial availability of human neurons, or brain cells, created from induced pluripotent stem (iPS) cells in the quantity, quality, and purity required for life science research.

iCell Neurons exhibit the typical physiological characteristics and responses of the neurons with which we are born. These neurons quickly form connective neuronal networks that are electrophysiologically active, making them useful in a variety of applications commonly used in neuroscience research, including cell viability, ATP production, oxidative stress, neurite outgrowth, electrophysiology, and synaptic neurotransmission assays. CDI's proprietary manufacturing capabilities enable the production of iCell Neurons in industrial quantities with greater than 95% purity.

CDI has successfully engaged in pre-launch collaborations with several pharmaceutical customers for validation testing and establishing disease-relevant neuroscience assays. "We have been working with CDI for some time now and are very impressed with their iCell Neurons, which provide us with a unique model of pure and highly differentiated human neurons showing real potential for measuring functional neurotransmission," said Dr. Pascal Laeng, Head of Molecular and Cellular Pharmacology at Galenea Corp. "The preliminary data are very promising, and we look forward to continued collaboration with CDI to implement iCell Neurons in our high throughput assay of synaptic function."

Dr. Johannes Mosbacher, Director of CNS Electrophysiology, Actelion
'/>"/>

SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
2. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
3. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
4. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
5. MIT, BU engineer cellular circuits that count events
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
7. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
8. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
9. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
10. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
11. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Associate Professor Catherine Pickering, said the Griffith study looked ... can be dispersed through horse manure. The findings have ... Restoration . "We reviewed 15 studies on seed ... North America, three from Australia and one study each ...
... , Nov. 7, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... its ongoing Phase 1 trial of KB004, an anti-EphA3 ... session at the 55 th American Society of ... trial of KB004 is a multi-center, dose-escalation study evaluating ...
... 7, 2013 The knowledge and skills required to change ... to those living with financial limitations. Competing demands on ... better diets. However, two researchers at the University ... the effects that three educational sessions might have on ...
Cached Biology News:Saddling up against the threat to our National Parks 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 3KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 4KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 53 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2
... Dawbarn and S.J. Allen (1995) ... by world authorities on current issues relating ... disease. Several major advances have been made ... this disease. Topics include molecular neuropathology through ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
biotin-4-fluorescein...
Biology Products: